Researchers at Adelaide University are investigating the potential health implications of a hidden ingredient in the oral formulations of popular weight loss medications, Wegovy and Ozempic. A recent animal study revealed that salcaprozate sodium (SNAC), which facilitates the absorption of the active ingredient semaglutide, may influence gut health and metabolic functions in ways that were previously unexamined.
Significance of SNAC in Semaglutide Tablets
Semaglutide is the key component in both medications, designed to assist with weight management by mimicking a hormone that regulates appetite. When administered via injection, semaglutide enters the bloodstream directly. However, in tablet form, it relies on SNAC to protect it from degradation by stomach enzymes and aid its absorption into the bloodstream. The United States approved an oral version of Wegovy in late 2025, leading to increased interest in the potential long-term effects of daily SNAC exposure.
The recent study, conducted over a 21-day period using an animal model, highlighted several noteworthy findings related to gut microbiota and inflammation markers. Although the research does not establish that SNAC is harmful to humans, it raises concerns about the broader biological impact of repeated exposure to this compound.
Addressing Obesity’s Global Challenge
The prevalence of obesity continues to escalate, affecting approximately 890 million adults and 160 million children worldwide. Among countries in the Organisation for Economic Co-operation and Development (OECD), the United States leads with a staggering 43% of individuals aged 15 and older classified as obese. Australia follows with a rate of 31%, surpassing the OECD average of 25%.
As demand for medications like Ozempic and Wegovy rises, understanding the implications of their ingredients becomes increasingly critical. Lead author Amin Ariaee, a PhD candidate at Adelaide University, emphasized the importance of comprehensively evaluating each component used in these medications. “Obesity is a complex, chronic disease with serious health consequences,” Ariaee noted. “While these medicines are highly effective and are helping many people, we need to understand the long-term effects of all ingredients in the pills, not just the active drug.”
Ariaee further elaborated on the study’s findings, indicating that SNAC was linked to shifts in potentially harmful gut bacteria, elevated inflammatory markers, and reductions in proteins associated with cognitive function. These results underscore the need for additional research to explore the full range of biological effects that SNAC may have.
Senior Research Fellow Dr. Paul Joyce cautioned that the study’s animal model should not be directly extrapolated to human health. “Our findings do not prove that SNAC causes harm in humans,” said Dr. Joyce. “However, they do suggest that the ingredient enabling these tablets to function may have adverse biological effects beyond drug absorption.”
As the use of these medications expands globally, it becomes increasingly essential to scrutinize all components of obesity treatments. The findings from this research could lead to a deeper understanding of how these drugs interact with the human body over time, particularly as oral formulations gain popularity.
This study, while preliminary, serves as a call to action for further investigation into the long-term consequences of daily exposure to SNAC. As the healthcare landscape continues to evolve, understanding the implications of such ingredients will be vital for ensuring patient safety and optimal health outcomes.
Story Source: Materials provided by Adelaide University. Note: Content may be edited for style and length.
